HPBT
CRSP icon

Hickory Point Bank & Trust’s CRISPR Therapeutics CRSP Stock Holding History

Hickory Point Bank & Trust’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.18K Hold
150
– – 0.01% 365
2026
Q1 		$7.14K Buy
+150
New +$7.91K ﹤0.01% 375

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Hickory Point Bank & Trust's CRSP Position: Q2 2026 in Review

Hickory Point Bank & Trust held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 150 shares worth $8.18K. The position accounts for 0.01% of the portfolio, ranked #365.

Hickory Point Bank & Trust first reported a position in CRSP in Q1 2026 and has held it in 2 quarters since. 252 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Hickory Point Bank & Trust held 150 shares of CRISPR Therapeutics worth $8.18K as of Q2 2026.
  • Hickory Point Bank & Trust left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up 0.01% of Hickory Point Bank & Trust's portfolio in Q2 2026, its #365 holding.
  • Hickory Point Bank & Trust first reported a position in CRISPR Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 252 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Hickory Point Bank & Trust's 13F filing for Q2 2026, filed 17 Jul 2026.